DescriptionThe activation or expression of ERBB2(HER2) is altered in many epithelial tumors and clinical studies have revealed its important role in cancer progression and metastasis. Consequently, its function in cancer biology and potential as a therapeutic target has been intensely studied. Identification of a novel interaction partner of HER2 that can be targeted to disrupt the HER2 pathway will thus be of clinical and pathophysiological relevance.
No resources found.
No links found.